secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001437749-23-034134
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics sells brachytherapy business to GT Medical
-------------------------------------------------------------------

- Transaction expected to close Q1 2024; assets include Cesium-131 seed IP, equipment, Richland, WA lease.
- Consideration: 0.5% equity in GT Medical plus tiered cash royalties over 4 years (3-5% on seed sales, 0.5% on GammaTile).
- Company retains most liabilities (environmental, warranty, taxes, accounts payable) and all accounts receivable.
- Sale aligns resources with lead-based alpha-particle therapy pipeline (melanoma VMT01, neuroendocrine VMT-α-NET).
- GT Medical gains control of Cesium-131 seed production, expanding its GammaTile Therapy customer base.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774923034134/0001437749-23-034134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774923034134/isr20231208_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-034134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer